Interview with Giulia, Molecular R&D Director
Giulia, how did your career in this company started?
Every year, DiaSorin funds some scholarships at the Bicocca University of Milan, where I graduated in Industrial Biotechnology. In 2007 I was selected for this unique opportunity: since then I have not left the company, growing up along its side.
How would you best describe your profession?
Evolution. We need to be up-to-date in the R&D department - it's a growing field. To improve in what we do, we need inspiration and knowledge, so we regularly attend medical congresses and end each day by sharing an interesting scientific article with the team.
You talked about a team: How important is that in your work?
It is essential. There are twenty-one people working in the Molecular Research and Development center: I want to know their projects and expectations, to create a more cohesive and winning group. Many of our best ideas come out during coffee breaks!
How is a new product born?
Every six months, the DiaSorin Scientific and Technological Committee meets to assess possible, future investments. Here, my team proposes new products, explaining the development timelines. We get a feedback from the marketing colleagues in order to evaluate their market potential. When a project is approved, its creation begins and in two or three years the kit is launched on the market.
Two or three years: it's a long time! How come the process is so long?
It is the time necessary for the development of reliable and excellent products which can provide accurate answers to doctors and their patients. The creation process runs in five phases: definition of the project specifications, pre-feasibility study, feasibility study, verification and validation. A path that requires deepening and that involves, in every step, different professional figures.
Let’s end this interview with a success: what is the project you are most proud of?
Surely the discovery of PML-RARA translocation. Our team has worked hard for years to develop the fastest molecular test in the world for the diagnosis of acute promyelocytic leukemia. The journey was long and required an intense effort, but being able to develop the final kit has surely a great reward for all our effort.